title: Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure.
abstract: Insulin-like growth factor I (IGF-I) enhances myofibrillar development in cardiomyocytes of rats in culture and in vivo. In addition, IGF-I has vasodilatory effects and improves cardiac function in healthy volunteers. This study was conducted to evaluate the acute hemodynamic effects of IGF-I in patients with chronic heart failure Eight patients with chronic heart failure were randomized to receive recombinant human IGF-I (60 micrograms/kg) or placebo, i.v., over 4 h in a cross-over, double blind study on 2 consecutive days. Electrocardiogram as well as systemic hemodynamics were continuously monitored over 7 h by flow-guided thermodilution and radial artery catheters. IGF-I was well tolerated by all patients, and no pathological changes on electrocardiogram were recorded. Compared with placebo, IGF-I increased the cardiac index by 27 +/- 3.7% (+/- SE; P < 0.0005) and the stroke volume index by 21 +/- 5.6% (P < 0.05), and decreased systemic vascular resistance by 28 +/- 4.4% (P < 0.0002), right atrial pressure by 33 +/- 9.0% (P < 0.003), and pulmonary artery wedge pressure by 25 +/- 6.1% (P < 0.03). Mean systemic and pulmonary artery pressure as well as heart rate and pulmonary vascular resistance were not significantly influenced by IGF-I treatment. Insulin and C peptide levels were decreased by IGF-I, whereas glucose and electrolyte levels remained unchanged. Urinary levels of norepinephrine decreased significantly (P < 0.05) during IGF-I infusion. Thus, acute administration of IGF-I in patients with chronic heart failure is safe and improves cardiac performance by afterload reduction and possibly by positive inotropic effects. Further investigations to establish whether the observed acute effects of IGF-I are maintained during chronic therapy appear to be warranted.
authors.affiliation: Division of Endocrinology, University Hospital, CH-8091 Zurich, Switzerland. ndosam@usz.unizh.ch
authors.forename: M Y
authors.initials: MY
authors.lastname: Donath
authors.forename: G
authors.initials: G
authors.lastname: Sütsch
authors.forename: X W
authors.initials: XW
authors.lastname: Yan
authors.forename: B
authors.initials: B
authors.lastname: Piva
authors.forename: H P
authors.initials: HP
authors.lastname: Brunner
authors.forename: Y
authors.initials: Y
authors.lastname: Glatz
authors.forename: J
authors.initials: J
authors.lastname: Zapf
authors.forename: F
authors.initials: F
authors.lastname: Follath
authors.forename: E R
authors.initials: ER
authors.lastname: Froesch
authors.forename: W
authors.initials: W
authors.lastname: Kiowski
mesh_terms: D000328:Adult; D002096:C-Peptide / Q000097:blood; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000503:physiopathology; D002319:Cardiovascular System / Q000503:physiopathology*; D002908:Chronic Disease; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D011994:Recombinant Proteins; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D002096:C-Peptide; D007328:Insulin; D010919:Placebos; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I